G2B Pharma Inc. is a privately-held developmental stage specialty pharmaceutical company, focused on the development of nasally delivered drugs, including nasally delivered epinephrine for the treatment of anaphylaxis. http://www.g2bpharma.com
Our primary product candidate, G2B011, is a nasal spray formulation of epinephrine for the treatment of anaphylaxis. Anaphylaxis is a severe and life-threatening allergic reaction that affects tens of millions of people worldwide. Common causes of anaphylactic reactions include food allergies and bee stings. Epinephrine is the gold standard for treatment of anaphylaxis and is currently provided for self-administration by injection. The company believes that nasal administration offers an effective and more patient-friendly delivery route for this life-saving medication.
August 2014. G2B Pharma announces the signing of an agreement with Sosei Group Corporation for development financing for G2B011, a needle-free nasal epinephrine formulation, and the signing of an option-for-license agreement with Shin Nippon Biomedical Laboratories, Ltd.for the use of SNBL’s µco™ System nasal delivery platform with the Fit-lizerTM nasal device for the product.
September 2013. G2B Pharma and Shin Nippon Biomedical Laboratories (SNBL) announce the completion of a feasibility study investigating a nasal epinephrine formulation incorporating both SNBL’s nasal delivery technology platform and G2B’s mucosal absorption technology for epinephrine. The study is part of a collaboration between the two companies for the development of a nasal epinephrine product for the treatment of anaphylaxis.